Biotech Analyst Thompson, along with Drs. Lester, Bard and Gaestel, provide their views on MK2 and the bar for clinical success in hidradenitis suppurativa on an Analyst/Industry conference call to be held on February 22 at 12 pm. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
- Stifel biotechnology analyst to hold an analyst/industry conference call
- Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
- Fly Insider Express, ServiceNow among week’s notable insider trades
- Aclaris Therapeutics provides corporate outlook for 2023